AstraZeneca announced results from a PLATO sub-analysis that evaluated the effect of smoking status on clinical outcomes in patients with acute coronary syndrome. This analysis suggests the overall findings from the PLATO study of greater reduction in thrombotic CV events with BRILINTA (ticagrelor) tablets plus aspirin compared to clopidogrel plus aspirin was consistent regardless of smoking habits. 1 These data, slated for publication in the September issue of American Heart Journal, are currently available online, and were previously presented at the American College of Cardiology 2012 meeting. "The potential impact of smoking on the effect of certain medications continues to be a topic of considerable interest and discussion among the cardiovascular community," stated James Ferguson, MD, Executive Director, Medical Affairs and Strategic Development, and Vice President for Global Medical Affairs. "This sub-analysis suggests that the clinical benefits of BRILINTA vs clopidogrel on thrombotic CV events shown in PLATO were not significantly affected by smoking status, and were similar in both smokers and non-smokers."
Apple's ability to shelter billions of dollars of income from tax has depended on an unusual loophole in the Irish …